UK Drugmaker GSK Transfers Malaria Vaccine Production To Bharat Biotech
Britain's GSK will shift production of the world's first effective malaria vaccine to Indian COVID-19 vaccine developer Bharat Biotech, as part of global efforts to battle the deadly fever, the drugmakers said on Wednesday.
The agreement includes transfer of manufacturing of the protein part of the vaccine, RTS,S/AS01, while GSK will continue to supply Bharat Biotech with the adjuvant or vaccine booster for the shot, the joint statement said.
The vaccine, developed by GSK for over three decades and with nonprofit group PATH since 2001, is currently being administered under a special World Health Organization-backed scheme in Ghana, Kenya, and Malawi.
Malaria is caused in humans by five types of parasites transmitted through the bite of a certain variety of infected female mosquitoes.
Two of these parasite variants, including Plasmodium falciparum, against which the GSK vaccine was developed, pose the greatest threat.